The decision in plain terms

When a consultant recommends a ChondroFiller injection before considering surgery, the reasoning is not that surgery has been ruled out — it is that the same repair mechanism can be delivered without it. ChondroFiller works through acellular matrix-induced chondrogenesis: a collagen scaffold that recruits the patient's own progenitor cells from the surrounding synovium and subchondral bone, providing the structural template that damaged cartilage cannot create for itself. That cell-recruitment process is identical whether the scaffold reaches the defect via an ultrasound-guided outpatient injection or an arthroscopic surgical procedure. What changes is the procedural burden, not the biology.

Removing general anaesthesia, theatre admission, incisions, and surgical recovery from the equation substantially shifts the risk/benefit calculation. A treatment that once required operating-theatre resources can now be delivered in a 30–45 minute in-clinic appointment at MSK Doctors, with no hospital stay and no surgical wound to manage. That shift makes early intervention proportionate rather than premature.

Timing matters here for a specific reason: articular cartilage is avascular, meaning it has no blood supply to carry repair signals to a focal defect. A chondral hole does not close on its own — it widens. Choosing the injection pathway first is not a compromise; it is an evidence-based decision to act before further joint tissue is lost.

Why cartilage defects worsen without treatment

The consequence of that biological limitation is progressive joint damage. A Grade 3 or 4 focal chondral defect — where cartilage loss exceeds 50% of its depth, or subchondral bone is fully exposed — does not stabilise: it expands at its margins as adjacent tissue is loaded unevenly and begins to break down. Over time, a treatable focal defect can transition into the diffuse joint degeneration that characterises end-stage osteoarthritis, at which point joint preservation is no longer a realistic aim.

ChondroFiller addresses this trajectory by supplying what the body cannot generate independently: a Type I collagen matrix that gels in situ over the defect surface, enabling acellular matrix-induced chondrogenesis. The patient's own progenitor cells — drawn from the synovium and underlying subchondral bone — migrate into the scaffold and begin the repair process. A 2025 ex vivo osteochondral study quantified this directly: ChondroFiller produced a 2.4-fold increase in DNA content within the scaffold by day 14 compared with an untreated defect control, confirming active cell recruitment rather than passive gap-filling.

The tissue that forms is hyaline-like in character — considerably closer to native cartilage than the fibrocartilage typically produced by microfracture, which is mechanically weaker and less durable under the cyclic loading a knee experiences daily. That difference in repair tissue quality is one reason the injection pathway is not simply a holding measure: it promotes endogenous repair that targets the defect's structural root cause.

Which patients are right for the injection pathway

Identifying the right patient comes down to two questions: is the damage focal and severe enough to warrant intervention, and is the joint still worth preserving?

The first question is answered by MRI. A focal Grade 3 or Grade 4 lesion — the grades outlined in the previous section — confirms that the defect is both deep enough to be clinically significant and structurally contained rather than diffuse. Focal means a discrete hole or zone of loss, not cartilage that has degraded broadly across the joint surface.

The second question concerns the surrounding joint. ChondroFiller targets joints that remain preservation candidates. Active infection within the joint, diffuse advanced osteoarthritis, immunosuppression, and poorly controlled diabetes all make a patient unsuitable. The clearest empirical evidence for where this boundary sits comes from a hip arthroscopy cohort: patients with pre-existing Tönnis Grade 2–3 osteoarthritis — a separate X-ray-based scale for overall joint degeneration, distinct from the focal cartilage grading used above — had poor outcomes, confirming that once background degeneration is established across the joint as a whole, not just at the focal defect, the scaffold cannot compensate for what is already lost.

Age is not a fixed barrier, but clinical series reflect where the treatment is most frequently applied. In a 2024 knee cohort of 17 patients, the mean age was 31 — typical of the active, younger population for whom joint preservation carries the greatest long-term value.

What the clinical evidence shows

The strongest available trial evidence comes from a prospective RCT directly comparing ChondroFiller with microfracture. In the ChondroFiller arm (13 patients), IKDC scores — a 0-to-100 patient-reported function scale where higher scores reflect better knee function — improved significantly at 3, 6, and 12 months, with no adverse events recorded. MRI at 52 weeks confirmed good defect filling and visible cartilage maturation.

The microfracture arm produced a finding that sits outside the usual bounds of a trial result: 6 of the 10 patients randomised to surgery declined once it was assigned to them. That 60% refusal rate is not a methodological shortcoming — it is a real-world preference signal captured within a controlled design, suggesting that patients who understand both options will, in considerable numbers, opt away from the surgical route.

Real-world UK clinic data report approximately 30 IKDC points of improvement at 12 months — a gain that, in practical terms, often corresponds to the difference between struggling on stairs and returning to low-impact activity — alongside low reoperation rates. MOCART scores, an MRI-based measure of how completely the scaffold has filled the structural defect, have been recorded in the range of 70–87 in reported series, providing an imaging-based counterpart to the patient-reported numbers.

The 2024 knee cohort described in the previous section contributed a further expectation-setter beyond its age profile: IKDC and Lysholm gains were significant at 3 and 6 months, but the difference between the 6- and 12-month assessments was not statistically meaningful — most functional recovery appears to occur within the first half-year. Current evidence supports these outcomes; it does not yet include a large-scale head-to-head RCT.

When surgery becomes the right next step

Surgery enters the picture when the defect itself — or the structural context around it — exceeds what an injectable scaffold can predictably manage.

Traditional surgical options each carry a meaningful procedural load. Microfracture involves perforating the subchondral bone to draw marrow cells into the defect; the tissue that forms is predominantly fibrocartilage rather than the hyaline-like cartilage the scaffold targets, and durability over the long term is more limited. Mosaicplasty transfers osteochondral plugs from a donor site, requiring intact donor cartilage elsewhere in the same joint. MACI (matrix-assisted chondrocyte implantation) adds a preliminary cell-harvest step before the implantation procedure itself. Osteochondral allograft draws on donor tissue to reconstruct the affected segment. Each approach requires entering the joint; several also involve bone work or tissue harvest with its own recovery arc.

The escalation logic follows defect characteristics: a lesion too large for reliable scaffold filling, underlying bone involvement, or co-existing mechanical instability each shift the balance towards a surgical route.

Between outpatient injection and more extensive reconstruction sits the Liquid Cartilage™ procedure — a keyhole technique pairing ChondroFiller with MSC co-delivery for defects where a single injection is insufficient but the joint does not yet require formal articular reconstruction. This graduated step reflects the same proportionality principle that places injection before open surgery: intervene at the least intensive level the clinical picture supports.

Because assessment, imaging, and treatment planning at MSK Doctors remain with the same consultant team throughout, a decision to escalate continues from an established clinical picture rather than requiring a referral restart.

Practical expectations: access, cost, and rehabilitation

Treatment is available without a GP referral and without NHS-style waiting times, but it is self-funded private care — not NHS-commissioned, and not routinely covered by UK private medical insurers. The guide cost from approximately £3,000 includes ultrasound guidance, the collagen scaffold product, and the injection itself; patients outside London can access the pathway at MSK Doctors' Sleaford and Grantham sites, which offer on-site MRI and consultant-led assessment in the same service setting.

One rehabilitation point deserves plain explanation. A 2024 biomechanical in vitro study found that freshly placed ChondroFiller did not reduce mechanical stress on the opposing cartilage surface under cyclic loading, attributing this to initial material instability before the scaffold has fully integrated. That finding is the mechanistic basis for a phased weight-bearing protocol — not a safety warning unique to this product, but the clinical reason return-to-loading is structured rather than left open-ended. Scaffold integration takes time, and the rehabilitation programme is built around that biology rather than around symptoms alone.

For patients who are candidates, the broader picture is one of proportionality: a focal, severe defect addressed at the right moment — before joint-wide deterioration sets in — through a pathway that preserves surgical options and avoids unnecessary procedural burden. That calculus is what places the injection before theatre, not optimism about a single product. Appointments at MSK Doctors are available without a GP referral at mskdoctors.com.

1. [1] Development of an Ex Vivo Osteochondral Biomimetic Platform for Mechanistic Investigation of Cartilage Regeneration. (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759
2. [2] Controlled, randomized multicenter study to compare ChondroFiller liquid with microfracturing for focal cartilage defects of the knee. (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1
3. [3] Implantation of ChondroFiller Liquid® as a scaffold material for the treatment of chondral lesions of the knee joint. (2024). https://doi.org/10.5272/jimab.2024304.5936 https://doi.org/10.5272/jimab.2024304.5936
4. [4] Influence of cartilage defects and a collagen gel on integrity of corresponding intact cartilage: a biomechanical in-vitro study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z
5. [5] Arthroscopic utilization of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12- to 60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002